Hyper-IgM Syndrome Type 2

Mendelian MONDO:0011528 Pathograph 16 Show in embeddings browser Primary Immunodeficiency Antibody Deficiency Disorder Hyper-IgM Syndrome

Hyper-IgM syndrome type 2 (HIGM2) is a primary antibody deficiency caused by biallelic loss-of-function variants in AICDA, encoding activation-induced cytidine deaminase (AID). AID is a B-cell-restricted cytidine deaminase expressed in germinal center B cells that initiates both immunoglobulin class-switch recombination (CSR) and somatic hypermutation (SHM) by deaminating cytosine residues in immunoglobulin switch and variable regions. Its loss therefore abolishes two distinct arms of antigen-driven antibody maturation at once: patients cannot switch from IgM to IgG, IgA, or IgE, and cannot introduce the mutations that underpin affinity maturation. The serum profile is the diagnostic signature — normal or elevated IgM with absent or very low IgG, IgA, and IgE, and normal numbers of circulating B cells. Clinically this produces recurrent bacterial sinopulmonary and mucosal infection from infancy, together with a hallmark massive lymphoid hyperplasia (lymphadenopathy and tonsillar enlargement driven by giant germinal centers) that is far more prominent than in most other antibody deficiencies. A substantial minority develop autoimmune or inflammatory disease, which is now understood mechanistically: AID is independently required for the removal of developing autoreactive B cells, so its loss breaches both central and peripheral B-cell tolerance. SCOPE AND CONTRAST. The defect is strictly B-cell intrinsic. This is the key distinction from the CD40L (HIGM1) and CD40 (HIGM3) hyper-IgM syndromes, where the same CSR block arises from failed T-cell-to-B-cell licensing and the same CD40 pathway is additionally required for macrophage and dendritic cell activation. Because T-cell and macrophage effector function is intact in AID deficiency, HIGM2 patients are not susceptible to the opportunistic infections (Pneumocystis, Cryptosporidium, and other fungal or protozoal organisms) that define the CD40L/CD40 forms, and hematopoietic cell transplantation is correspondingly not a routine indication. The IUIS 2022 classification records the same split: AID deficiency sits in Table 3 (predominantly antibody deficiencies) whereas CD40LG and CD40 deficiency sit in Table 1 (combined immunodeficiencies). This entry covers the autosomal recessive disease as its primary subject; a rarer autosomal dominant form caused by heterozygous C-terminal AICDA variants, in which the CSR defect occurs with preserved SHM, is curated here as a distinct genetic and inheritance context rather than as a separate entry.

Ask OpenScientist

Ask a research question about Hyper-IgM Syndrome Type 2. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Inheritance
11
Pathophys.
15
Phenotypes
2
Gaps
16
Pathograph
2
Genes
1
Variants
3
Medical Actions
2
Differentials
10
References
🏷

Classifications

Harrison's Part
IMMUNE RHEUMATOLOGIC GENETICS ENVIRONMENT DISEASE
IUIS Category
predominantly antibody deficiency
👪

Inheritance

2
Autosomal recessive inheritance HP:0000007
The classic form of HIGM2 is inherited as an autosomal recessive trait, caused by mutations affecting both AICDA alleles.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:11007475 SUPPORT Human Clinical
"We herein report mutations in the human counterpart of AID in patients with the autosomal recessive form of hyper-IgM syndrome (HIGM2)."
The gene-discovery study establishes AICDA mutations as the cause of the autosomal recessive form of hyper-IgM syndrome.
PMID:15893695 SUPPORT Human Clinical
"Autosomal recessive form of hyper-IgM syndrome type 2 (AR-HIGM2) is secondary to mutations affecting both alleles of AICDA gene encoding activation-induced cytidine deaminase"
Confirms that the recessive disease requires mutation of both AICDA alleles.
Autosomal dominant inheritance HP:0000006
A rarer autosomal dominant form (AD-HIGM2) is caused by heterozygous variants affecting the C-terminal region of AID, classically the R190X nonsense variant. The C-terminus is required for the DNA-repair steps specific to class-switch recombination but not for somatic hypermutation, so these patients have a variable CSR defect with preserved SHM. IUIS 2022 Table 3 lists this dominant AICDA form as its own row (OMIM 605257) alongside the recessive row, and records that the causal variants localise uniquely to the nuclear export signal; those row fragments are too short and too corrupted by PDF text extraction to quote as standalone evidence, so the published patient series are cited instead.
Autosomal dominant inheritance
Show evidence (2 references)
PMID:15893695 SUPPORT Human Clinical
"Variable defect in in vivo CSR inherited as an autosomal dominant (AD) trait strongly suggests that this heterozygous AICDA mutation causes HIGM (AD-HIGM2)."
Establishes a dominantly inherited form of HIGM2 caused by a single heterozygous AICDA variant.
PMID:32423680 SUPPORT Human Clinical
"The genetic investigation of a family presenting with a dominant form of hyper IgM syndrome published in 1963 and 1975 revealed a R190X nonsense mutation in activation-induced cytidine deaminase."
An independent kindred with dominantly inherited hyper-IgM syndrome resolved to a heterozygous R190X AICDA variant.
?

Discussions and Knowledge Gaps

2
What is the population prevalence of AID deficiency, and does it differ between populations with high and low rates of consanguinity?
KNOWLEDGE GAP OPEN higm2_population_prevalence_unknown
Attached to
Every published estimate of HIGM2 frequency is a referral-based case count rather than a denominator-based rate, so the disease's true prevalence is unknown. Because it is autosomal recessive, prevalence should be markedly higher in populations with high consanguinity — the original cohorts drew heavily on Turkish and Middle Eastern families — but no population-based screening study has tested this. Without a denominator it is impossible to say what fraction of AID-deficient people are diagnosed, and the consistently mild infectious phenotype relative to CD40L deficiency makes under-ascertainment plausible.
Is the tolerance defect in AID deficiency a direct consequence of losing deaminase activity in developing B cells, or an indirect consequence of the abnormal germinal-center environment?
KNOWLEDGE GAP OPEN higm2_aid_tolerance_direct_or_indirect
AID is required for removal of autoreactive B cells at both the central and peripheral checkpoints, but the central checkpoint operates in the bone marrow, before B cells enter a germinal center and before AID is conventionally described as being expressed. Whether the tolerance defect reflects a distinct, low-level developmental role for AID or is secondary to systemic effects of the failed germinal-center reaction is unresolved, and it determines whether autoimmunity in HIGM2 could be predicted from genotype or only observed.

Pathophysiology

11
AID Enzymatic Loss of Function
Activation-induced cytidine deaminase is a member of the cytidine deaminase family whose expression is restricted to germinal center B cells. It initiates antibody diversification by deaminating cytosine to uracil in single-stranded DNA at the immunoglobulin switch and variable regions, creating the U:G mismatches that downstream repair pathways convert into either switch-region double-strand breaks or point mutations. Biallelic loss-of-function AICDA variants abolish this enzymatic activity, removing the single upstream trigger for both antibody-diversification programs. Anchors the module's conformance here rather than on either downstream node (Failed Immunoglobulin Class-Switch Recombination, Failed Somatic Hypermutation) because this is the molecular lesion that causes both of them: neither downstream node alone covers the module's bundled "Germinal Center Reaction" claim, but this one node, read alongside its two direct downstream edges, does.
Germinal center B cell CL:0000844 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Germinal center B cell (CL:0000844). CL:0000844 is a cell type from the Cell Ontology.
Somatic Hypermutation of Immunoglobulin Genes GO:0016446 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves absent Somatic Hypermutation of Immunoglobulin Genes (GO:0016446). GO:0016446 is a biological process from the Gene Ontology. ∅ ABSENT Class Switch Recombination GO:0045190 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves absent Class Switch Recombination, annotated with isotype switching (GO:0045190). GO:0045190 is a biological process from the Gene Ontology. ∅ ABSENT
cytidine deaminase activity GO:0004126 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves cytidine deaminase activity (GO:0004126), qualified as loss of function. GO:0004126 is a molecular function from the Gene Ontology. ⇓ LOSS OF FUNCTION
Show evidence (1 reference)
PMID:11007475 SUPPORT Human Clinical
"The activation-induced cytidine deaminase (AID) gene, specifically expressed in germinal center B cells in mice, is a member of the cytidine deaminase family."
Identifies AID as a germinal-center-B-cell-restricted cytidine deaminase, grounding the enzymatic activity and cell type of this node.
Failed Immunoglobulin Class-Switch Recombination
Class-switch recombination replaces the IgM/IgD constant region with a downstream constant region, converting a naive B cell's output to IgG, IgA, or IgE without altering antigen specificity. In AID deficiency this recombination does not occur. The block is B-cell intrinsic: germline switch transcripts are still produced and the upstream T-cell help signal is intact, so the lesion lies at the DNA-modification step itself.
Germinal center B cell CL:0000844 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Germinal center B cell (CL:0000844). CL:0000844 is a cell type from the Cell Ontology.
Immunoglobulin isotype switching GO:0045190 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Immunoglobulin isotype switching, annotated with isotype switching (GO:0045190), qualified as loss of function. GO:0045190 is a biological process from the Gene Ontology. ⇓ LOSS OF FUNCTION
Show evidence (2 references)
PMID:11007474 SUPPORT Model Organism
"AID-/- spleen cells stimulated in vitro with LPS and cytokines failed to undergo class switch recombination although they expressed germline transcripts."
The AID-knockout mouse shows the switch block is at the recombination step itself, downstream of germline transcription — evidence from a model organism that defines where in the pathway the lesion sits.
PMID:17560278 SUPPORT Other
"the description of the activation-induced cytidine deaminase (AID) deficiency (Ig-CSR deficiency 1), caused by recessive mutations of AICDA gene, characterized by a defect in CSR and SHM"
A review of the CSR deficiencies characterizes recessive AICDA mutation as producing a combined CSR and SHM defect.
Failed Somatic Hypermutation
Somatic hypermutation introduces point mutations into immunoglobulin variable-region genes, generating the sequence variation on which affinity-based selection acts in the germinal center. AID deficiency abolishes it. Memory B cells are still generated in normal numbers but carry unmutated variable regions. This arm is independent of the CSR arm: C-terminal AICDA variants can spare it while still blocking CSR.
Germinal center B cell CL:0000844 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Germinal center B cell (CL:0000844). CL:0000844 is a cell type from the Cell Ontology. Memory B cell CL:0000787 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Memory B cell (CL:0000787). CL:0000787 is a cell type from the Cell Ontology.
Somatic hypermutation of immunoglobulin genes GO:0016446 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Somatic hypermutation of immunoglobulin genes (GO:0016446), qualified as loss of function. GO:0016446 is a biological process from the Gene Ontology. ⇓ LOSS OF FUNCTION
Show evidence (2 references)
PMID:35748970 SUPPORT Other
"memory B cells but lacking"
The IUIS Table 3 immunologic column for the recessive AICDA row records normal memory B cells that nonetheless lack somatic hypermutation.
PMID:11007474 SUPPORT Model Organism
"Immunization of AID-/- chimera with 4-hydroxy-3-nitrophenylacetyl (NP) chicken gamma-globulin induced neither accumulation of mutations in the NP-specific variable region gene nor class switching."
Antigen challenge of AID-deficient mice produced no variable-region mutation, demonstrating that AID is required for somatic hypermutation in vivo.
IgM-Restricted Antibody Repertoire
The systemic consequence of the switching block is a humoral compartment that produces only IgM. Serum IgM is normal or elevated — partly because unswitched B cells continue to be driven by antigen — while IgG, IgA, and IgE are absent or very low. Circulating B-cell numbers are normal, which distinguishes HIGM2 from the agammaglobulinemias, where the lesion is a developmental block upstream of B-cell egress.
Plasma cell CL:0000786 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Plasma cell (CL:0000786). CL:0000786 is a cell type from the Cell Ontology. B cell CL:0000236 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves B cell (CL:0000236). CL:0000236 is a cell type from the Cell Ontology.
Immunoglobulin production GO:0002377 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Immunoglobulin production (GO:0002377). GO:0002377 is a biological process from the Gene Ontology. ↓ DECREASED
Show evidence (2 references)
PMID:35748970 SUPPORT Other
"3. Severe Reduction in Serum IgG and IgA with Normal/Elevated IgM and Normal Numbers of B cells, Hyper IgM"
The IUIS section heading defining this disease group states the exact composition of this node: severely reduced IgG and IgA, normal or elevated IgM, and normal numbers of circulating B cells.
PMID:36931691 SUPPORT Human Clinical
"Blood investigations revealed increased IgM levels with reduced IgG, IgA and IgE levels."
A genetically confirmed HIGM2 patient shows the characteristic isotype profile of raised IgM with all three switched isotypes reduced.
Absent Affinity Maturation
Memory B cells are produced but their variable regions remain in germline configuration, so the antibody repertoire never improves in affinity across repeated antigen encounters. Secondary responses are therefore no better than primary ones, compounding the isotype deficit.
Memory B cell CL:0000787 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Memory B cell (CL:0000787). CL:0000787 is a cell type from the Cell Ontology.
Somatic hypermutation of immunoglobulin genes GO:0016446 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Somatic hypermutation of immunoglobulin genes (GO:0016446), qualified as loss of function. GO:0016446 is a biological process from the Gene Ontology. ⇓ LOSS OF FUNCTION
Show evidence (1 reference)
PMID:11007475 SUPPORT Human Clinical
"The phenotype observed in HIGM2 patients (and in AID-/- mice) demonstrates the absolute requirement for AID in several crucial steps of B cell terminal differentiation necessary for efficient antibody responses."
AID is required for the terminal B-cell differentiation steps underlying efficient antibody responses; affinity maturation is the step this node represents.
Loss of Opsonizing and Mucosal Antibody Function
The two arms converge here. The patient retains antibody, but it is of the wrong isotype and of germline affinity: no IgG to opsonize encapsulated bacteria and fix complement efficiently in tissue, no secretory IgA to exclude organisms at respiratory and gastrointestinal mucosal surfaces, and no affinity-matured binding to compensate. Humoral protection against extracellular bacteria is therefore lost, while cellular immunity is untouched.
Complement activation and opsonization by antibody GO:0006956 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Complement activation and opsonization by antibody, annotated with complement activation (GO:0006956). GO:0006956 is a biological process from the Gene Ontology. ↓ DECREASED
Show evidence (1 reference)
PMID:14962793 SUPPORT Human Clinical
"Most patients had suffered from recurrent and severe infections, however, intravenous immunoglobulin (IVIG) replacement therapy resulted in a dramatic decrease in the number of infections."
That replacing IgG largely abolishes the infections demonstrates the infections are caused by the missing antibody function rather than by any cellular defect.
Recurrent Bacterial Sinopulmonary and Mucosal Infection
Clinically the infections are bacterial and mucosal — recurrent sinusitis, otitis media, and pneumonia progressing to bronchiectasis, with gastrointestinal involvement. The spectrum is narrower than in the CD40L/CD40 hyper-IgM syndromes: because AID acts only in B cells and leaves T-cell and macrophage effector function intact, HIGM2 patients do not show the Pneumocystis, Cryptosporidium, and other opportunistic infections that characterize the CD40 pathway defects. Immunoglobulin replacement markedly reduces infection frequency.
Show evidence (2 references)
PMID:24402618 SUPPORT Human Clinical
"Previously undescribed fungal and opportunistic infections were observed in CD40L-deficient patients but not in the two patients with AID deficiency."
Direct within-registry comparison showing opportunistic and fungal infections occurred in the CD40L form but not in AID deficiency — the clinical signature of a B-cell-intrinsic rather than combined defect.
PMID:36931691 SUPPORT Human Clinical
"Radiological imaging of the chest revealed bilateral bronchiectasis."
Illustrates the end-organ consequence of untreated recurrent sinopulmonary bacterial infection in a genetically confirmed HIGM2 patient.
Giant Germinal Center Formation
The histological hallmark of AID deficiency. B cells that cannot complete the diversification program are repeatedly restimulated and re-enter the germinal center rather than exiting as switched or affinity-matured progeny. Germinal centers consequently become greatly enlarged and are packed with strongly activated B cells — the "giant germinal centers" described in the original report and reproduced in AID-null mice.
Germinal center B cell CL:0000844 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Germinal center B cell (CL:0000844). CL:0000844 is a cell type from the Cell Ontology.
Germinal center formation GO:0002467 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Germinal center formation (GO:0002467). GO:0002467 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (1 reference)
PMID:11007475 SUPPORT Human Clinical
"lymph node hyperplasia caused by the presence of giant germinal centers"
Names giant germinal centers as the third cardinal abnormality of AID deficiency and as the cause of the lymph node hyperplasia.
Massive Lymphoid Hyperplasia
Generalized enlargement of secondary lymphoid tissue — lymphadenopathy and tonsillar enlargement — is present in the majority of patients and is disproportionate to that seen in other primary antibody deficiencies. It can regress on immunoglobulin replacement but persists in a minority.
Show evidence (1 reference)
PMID:14962793 SUPPORT Human Clinical
"Lymphoid hyperplasia developed in 22 patients and persisted in 7 at last follow-up."
Quantifies lymphoid hyperplasia in 22 of the 29-patient cohort, and shows that it resolves in most but persists in some.
Breakdown of B-Cell Self-Tolerance
AID has a role in B-cell tolerance that is separable from its diversification role. In AID-deficient patients both the central checkpoint (new emigrant/transitional B cells) and the peripheral checkpoint (mature naive B cells) fail to remove autoreactive clones, and anti-nuclear IgM is detectable in serum. This provides the mechanistic explanation for the autoimmunity seen in a disease that is otherwise one of immune deficiency.
B cell CL:0000236 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves B cell (CL:0000236). CL:0000236 is a cell type from the Cell Ontology.
B cell tolerance induction GO:0002514 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves B cell tolerance induction (GO:0002514), qualified as loss of function. GO:0002514 is a biological process from the Gene Ontology. ⇓ LOSS OF FUNCTION
Show evidence (1 reference)
PMID:21700883 SUPPORT Human Clinical
"B-cell tolerance was further breached in AID-deficient patients as illustrated by the detection of anti-nuclear IgM antibodies in the serum of all patients."
Anti-nuclear IgM in all patients tested demonstrates a breached tolerance checkpoint in human AID deficiency.
Autoimmune and Inflammatory Disease
A substantial minority of AID-deficient patients develop autoimmune or inflammatory disease. The reported spectrum is broad and not confined to one organ — autoimmune cytopenias (hemolytic anemia, immune thrombocytopenia), polyarthritis, autoimmune hepatitis, type 1 diabetes, Crohn's disease, and chronic uveitis have all been described in a single cohort.
Show evidence (1 reference)
PMID:14962793 SUPPORT Human Clinical
"It is striking to note that six patients developed autoimmune or inflammatory disorders including diabetes mellitus, polyarthritis, autoimmune hepatitis, hemolytic anemia, immune thrombocytopenia, Crohn's disease and chronic uveitis."
Six of 29 cohort patients developed autoimmune or inflammatory disease, establishing both the frequency band and the organ spectrum.

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hyper-IgM Syndrome Type 2 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

15
Blood 6
Lymphoid Hyperplasia FREQUENT HP:0034839 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Lymphoid hyperplasia (HP:0034839). HP:0034839 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:14962793 SUPPORT Human Clinical
"Lymphoid hyperplasia developed in 22 patients and persisted in 7 at last follow-up."
22 of 29 patients (76%) developed lymphoid hyperplasia, placing it in the FREQUENT band (30-79%).
Increased Circulating IgM VERY_FREQUENT Increased circulating IgM level HP:0003496 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Increased circulating IgM level (HP:0003496). HP:0003496 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17560278 SUPPORT Other
"characterized by normal or elevated serum IgM levels and an absence or very low levels of IgG, IgA, and IgE"
Normal-to-elevated IgM is definitional for this disease group, supporting the VERY_FREQUENT band.
Decreased Circulating IgG VERY_FREQUENT Decreased circulating IgG concentration HP:0004315 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Decreased circulating IgG concentration (HP:0004315). HP:0004315 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17560278 SUPPORT Other
"an absence or very low levels of IgG, IgA, and IgE"
Absent or very low IgG is definitional for the Ig-CSR deficiencies, supporting the VERY_FREQUENT band.
Decreased Circulating IgA VERY_FREQUENT Decreased circulating IgA concentration HP:0002720 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Decreased circulating IgA concentration (HP:0002720). HP:0002720 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17560278 SUPPORT Other
"an absence or very low levels of IgG, IgA, and IgE"
Absent or very low IgA is definitional for the Ig-CSR deficiencies, supporting the VERY_FREQUENT band.
Autoimmune Hemolytic Anemia HP:0001890 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autoimmune hemolytic anemia (HP:0001890). HP:0001890 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:14962793 SUPPORT Human Clinical
"It is striking to note that six patients developed autoimmune or inflammatory disorders including diabetes mellitus, polyarthritis, autoimmune hepatitis, hemolytic anemia, immune thrombocytopenia, Crohn's disease and chronic uveitis."
Hemolytic anemia is named among the autoimmune disorders occurring in the cohort. The six affected patients span seven listed conditions, so individual manifestations were reported in only one or two patients each and no per-manifestation frequency band is asserted.
Autoimmune Thrombocytopenia HP:0001973 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autoimmune thrombocytopenia (HP:0001973). HP:0001973 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:14962793 SUPPORT Human Clinical
"It is striking to note that six patients developed autoimmune or inflammatory disorders including diabetes mellitus, polyarthritis, autoimmune hepatitis, hemolytic anemia, immune thrombocytopenia, Crohn's disease and chronic uveitis."
Immune thrombocytopenia is named among the autoimmune disorders in the cohort. Reported in one or two patients, so no frequency band is asserted.
Cardiovascular 2
Lymphadenopathy HP:0002716 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Lymphadenopathy (HP:0002716). HP:0002716 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:11007475 SUPPORT Human Clinical
"lymph node hyperplasia caused by the presence of giant germinal centers"
Lymph node hyperplasia from giant germinal centers is one of the three cardinal abnormalities of AID deficiency.
PMID:35748970 SUPPORT Other
"Bacterial infections, enlarged lymph nodes and"
The IUIS Table 3 associated-features column for AID deficiency lists enlarged lymph nodes alongside bacterial infections.
Enlarged Tonsils HP:0030812 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Enlarged tonsils (HP:0030812). HP:0030812 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36931691 SUPPORT Human Clinical
"bilateral purulent ear discharge since childhood with tonsillar enlargement on examination"
Tonsillar enlargement was an examination finding in a genetically confirmed HIGM2 patient. A single case report, so no frequency band is asserted.
Digestive 1
Crohn's Disease HP:0100280 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Crohn's disease (HP:0100280). HP:0100280 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:14962793 SUPPORT Human Clinical
"immune thrombocytopenia, Crohn's disease and chronic uveitis"
Crohn's disease is named among the inflammatory disorders in the cohort.
Ear 1
Otitis Media HP:0000388 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Chronic suppurative otitis media, annotated with Otitis media (HP:0000388). HP:0000388 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36931691 SUPPORT Human Clinical
"Otoscopic examination showed features suggestive of chronic suppurative otitis media."
Chronic suppurative otitis media in a genetically confirmed HIGM2 patient.
Immune 2
Recurrent Bacterial Infections VERY_FREQUENT HP:0002718 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Recurrent bacterial infections (HP:0002718). HP:0002718 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:14962793 SUPPORT Human Clinical
"Most patients had suffered from recurrent and severe infections"
"Most patients" in the 29-patient cohort supports the VERY_FREQUENT band for recurrent infection.
PMID:35748970 SUPPORT Other
"Bacterial infections, enlarged lymph nodes and"
IUIS lists bacterial infection as the leading associated feature of AID deficiency.
Autoimmune and Inflammatory Manifestations OCCASIONAL Autoimmunity HP:0002960 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autoimmune and inflammatory disease, annotated with Autoimmunity (HP:0002960). HP:0002960 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:14962793 SUPPORT Human Clinical
"It is striking to note that six patients developed autoimmune or inflammatory disorders including diabetes mellitus, polyarthritis, autoimmune hepatitis, hemolytic anemia, immune thrombocytopenia, Crohn's disease and chronic uveitis."
6 of 29 patients (21%) is within the OCCASIONAL band (5-29%), and the sentence enumerates the organ spectrum.
Musculoskeletal 1
Arthritis HP:0001369 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Polyarthritis, annotated with Arthritis (HP:0001369). HP:0001369 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:14962793 SUPPORT Human Clinical
"It is striking to note that six patients developed autoimmune or inflammatory disorders including diabetes mellitus, polyarthritis, autoimmune hepatitis, hemolytic anemia, immune thrombocytopenia, Crohn's disease and chronic uveitis."
Polyarthritis is named among the autoimmune and inflammatory disorders in the cohort. Reported in one or two patients, so no frequency band is asserted.
Respiratory 1
Bronchiectasis HP:0002110 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bronchiectasis (HP:0002110). HP:0002110 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36931691 SUPPORT Human Clinical
"Radiological imaging of the chest revealed bilateral bronchiectasis."
Bilateral bronchiectasis in a genetically confirmed HIGM2 patient. Single case report, so no frequency band is asserted.
Other 1
Autoimmune Hepatitis HP:5210421 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autoimmune hepatitis (HP:5210421). HP:5210421 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:14962793 SUPPORT Human Clinical
"It is striking to note that six patients developed autoimmune or inflammatory disorders including diabetes mellitus, polyarthritis, autoimmune hepatitis, hemolytic anemia, immune thrombocytopenia, Crohn's disease and chronic uveitis."
Autoimmune hepatitis is named among the autoimmune disorders in the cohort. Reported in one or two patients, so no frequency band is asserted.
🧬

Genetic Associations

2
AICDA (Causative)
Gene: AICDA hgnc:13203 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is AICDA (hgnc:13203). hgnc:13203 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:11007475 SUPPORT Human Clinical
"We herein report mutations in the human counterpart of AID in patients with the autosomal recessive form of hyper-IgM syndrome (HIGM2)."
The gene-discovery study identifying AICDA mutations as causative for HIGM2.
PMID:14962793 SUPPORT Human Clinical
"Fifteen distinct AID mutations were found but there was no significant genotype-phenotype correlation."
Documents allelic heterogeneity at AICDA without a genotype-phenotype correlation.
AICDA C-terminal heterozygous variants (autosomal dominant HIGM2) (Causative)
Gene: AICDA hgnc:13203 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is AICDA (hgnc:13203). hgnc:13203 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (3 references)
PMID:15893695 SUPPORT Human Clinical
"We herein report the immunological phenotype of seven patients carrying a single heterozygous R190X mutation in AICDA."
Seven patients with a single heterozygous R190X AICDA variant define the dominant form.
PMID:15893695 SUPPORT Human Clinical
"The characteristics of the AD-HIGM2 phenotype indicate that the AID C-terminal region may be involved in DNA repair machinery required for CSR."
Attributes the CSR-selective defect to loss of a C-terminal DNA-repair function, the mechanistic basis of this genetic context.
PMID:32423680 SUPPORT Human Clinical
"The genetic investigation of a family presenting with a dominant form of hyper IgM syndrome published in 1963 and 1975 revealed a R190X nonsense mutation in activation-induced cytidine deaminase."
Independent confirmation that R190X underlies a dominantly inherited hyper-IgM syndrome, in a family followed for six decades.
Variants (1)
AICDA R190X
Gene: AICDA hgnc:13203 HUGO Gene Nomenclature Committee (hgnc) Relation: this variant is in this gene This variant is in AICDA (hgnc:13203). hgnc:13203 is a gene from the HUGO Gene Nomenclature Committee. nonsense
Heterozygous C-terminal nonsense variant removing the AID nuclear export signal. Causes a class-switch-recombination defect with preserved somatic hypermutation, inherited as an autosomal dominant trait.
Show evidence (1 reference)
PMID:15893695 SUPPORT Human Clinical
"We herein report the immunological phenotype of seven patients carrying a single heterozygous R190X mutation in AICDA."
Identifies R190X as the recurrent heterozygous AICDA variant underlying the dominant form, in a series of seven patients.
💊

Medical Actions

3
Immunoglobulin Replacement Therapy
Action: immunoglobulin replacement therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is immunoglobulin replacement therapy, annotated with Immunoglobulin Therapy (NCIT:C62710). NCIT:C62710 is a clinical intervention from the NCI Thesaurus. Ontology label: Immunoglobulin Therapy NCIT:C62710
Platform: Other
Regular intravenous or subcutaneous immunoglobulin replacement is the cornerstone of management. It supplies the IgG that patients cannot make and produces a marked reduction in infection frequency; early initiation may also prevent the lymphoid hyperplasia. It does not correct the underlying enzymatic defect.
Mechanism Target:
BYPASSES Loss of Opsonizing and Mucosal Antibody Function — Passive IgG supplies the opsonizing antibody the patient cannot generate, bypassing rather than repairing the class-switch block.
Show evidence (1 reference)
PMID:14962793 SUPPORT Human Clinical
"intravenous immunoglobulin (IVIG) replacement therapy resulted in a dramatic decrease in the number of infections"
IVIG replacement dramatically reduced infections in the cohort, confirming it substitutes for the missing antibody function.
INHIBITS Massive Lymphoid Hyperplasia — Early-onset immunoglobulin replacement may prevent the lymphoid hyperplasia as well as the infections.
Show evidence (1 reference)
PMID:14962793 SUPPORT Human Clinical
"AID-deficient patients are prone to infections and lymphoid hyperplasia, which may be prevented by early-onset IVIG replacement"
The authors conclude that early IVIG may prevent lymphoid hyperplasia as well as infection; "may" is preserved here as a hedged claim.
Show evidence (1 reference)
PMID:36931691 SUPPORT Human Clinical
"The patient was started on monthly intravenous immunoglobulin replacement therapy and is currently symptomatically better"
Monthly IVIG is the treatment given to a genetically confirmed HIGM2 patient, with symptomatic improvement.
Antibiotic Therapy and Prophylaxis
Action: antibiotic therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antibiotic therapy (NCIT:C15620). NCIT:C15620 is a clinical intervention from the NCI Thesaurus. Ontology label: Antibiotic Therapy NCIT:C15620
Platform: Small molecule
Antibiotics treat the recurrent bacterial sinopulmonary and mucosal infections, and prophylactic regimens are used alongside immunoglobulin replacement in patients with continuing infection or established bronchiectasis.
Mechanism Target:
INHIBITS Recurrent Bacterial Sinopulmonary and Mucosal Infection — Antibiotics eradicate or suppress the bacterial infections that the missing switched antibody cannot prevent or clear.
Hematopoietic Cell Transplantation (rarely indicated)
Action: hematopoietic cell transplantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is hematopoietic cell transplantation (NCIT:C15431). NCIT:C15431 is a clinical intervention from the NCI Thesaurus. Ontology label: Hematopoietic Cell Transplantation NCIT:C15431
Platform: Cell therapy
Unlike the CD40L and CD40 hyper-IgM syndromes — where the combined immunodeficiency and its opportunistic infections make transplantation a standard consideration — HIGM2 is a B-cell-intrinsic antibody deficiency that is generally well controlled by immunoglobulin replacement, and transplantation is not a routine indication. This entry records the contrast rather than asserting a HIGM2 transplantation indication: in the Latin American registry the transplanted patients were CD40L-deficient, and all AID-deficient patients were alive on conventional management.
Show evidence (1 reference)
PMID:24402618 SUPPORT Human Clinical
"Four CD40L-deficient patients underwent successful bone marrow transplantation."
In the registry transplantation was performed in CD40L-deficient patients; none of the AID-deficient patients was transplanted, supporting the statement that HSCT is not a routine HIGM2 indication.
🔬

Diagnosis

2
Immunoglobulin panel showing the hyper-IgM pattern
The entry point is the serum immunoglobulin profile shared by every hyper-IgM syndrome: normal or elevated IgM with absent or decreased IgG, IgA and IgE. This identifies the syndrome but not the gene, which is why molecular testing follows.
serum immunoglobulin measurement NCIT:C18020 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:24402618 SUPPORT Human Clinical
"Hyper-IgM (HIGM) syndrome is a heterogeneous group of disorders characterized by normal or elevated serum IgM levels associated with absent or decreased IgG, IgA and IgE."
States the laboratory pattern that defines the clinical phenotype before the causal gene is known.
Molecular genetic testing of AICDA
Because the hyper-IgM laboratory pattern is shared across genes, the diagnosis of AID deficiency rests on identifying biallelic AICDA variants (or the dominant C-terminal allele). In the Latin American registry only 37 of 58 clinically diagnosed patients had a molecular defect identified, so a negative panel does not exclude the syndrome.
molecular genetic testing NCIT:C19770 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:24402618 SUPPORT Human Clinical
"Of the 58 patients from 51 families reported to the registry with the clinical phenotype of HIGM syndrome, molecular defects were identified in 37 patients thus far."
Quantifies the molecular yield against the clinical phenotype in a registry cohort.
PMID:14962793 SUPPORT Human Clinical
"Fifteen distinct AID mutations were found but there was no significant genotype-phenotype correlation."
Establishes the allelic heterogeneity found on sequencing, and that the variant identified does not predict severity.
📈

Progression

1
Diagnosis and long-term follow-up
Age: Median 4.9 years at diagnosis (range 0-53); median 14.2 years at last evaluation (range 2.7-63)
AID deficiency is not a neonatal presentation: in the 29-patient European cohort the median age at diagnosis was nearly five years, and patients were followed into adulthood, with the oldest evaluated at 63. Lymphoid hyperplasia developed in 22 of 29 patients but persisted in only 7 at last follow-up, so the germinal-center hyperplasia is not uniformly progressive.
Show evidence (2 references)
PMID:14962793 SUPPORT Human Clinical
"Patients' median age at diagnosis and at last evaluation was 4.9 years (range: 0 to 53) and 14.2 years (range: 2.7 to 63), respectively."
Gives the diagnostic delay and the follow-up span in the defining cohort.
PMID:14962793 SUPPORT Human Clinical
"Lymphoid hyperplasia developed in 22 patients and persisted in 7 at last follow-up."
Documents that the lymphoid hyperplasia regresses in most patients rather than progressing.
📊

Prevalence

1
Worldwide
Cases In Literature Ultra Rare
No population-based prevalence estimate for HIGM2 has been published. The disease is known from small international case series: the largest dedicated cohort assembled 29 patients from 22 families across multiple European and Middle Eastern referral centres. Registry data give a sense of its rarity relative to the CD40L form — in the Latin American HIGM registry only 2 of 37 molecularly defined hyper-IgM patients had AID deficiency, against 35 with CD40L deficiency. Both figures are referral-based counts, not denominators, so no rate per 100,000 is asserted here.
Show evidence (2 references)
PMID:14962793 SUPPORT Human Clinical
"We retrospectively analyzed clinical, immunologic and genetic characteristics of 29 patients from 22 families with AID deficiency."
The largest dedicated AID-deficiency cohort comprises 29 patients from 22 families worldwide, consistent with an ultra-rare disease reported as case series rather than population rates.
PMID:24402618 SUPPORT Human Clinical
"CD40 ligand (CD40L) deficiency was found in 35 patients from 25 families and activation-induced cytidine deaminase (AID) deficiency in 2 unrelated patients."
In a multinational hyper-IgM registry AID deficiency accounted for only 2 of 37 genetically defined patients, indicating it is a small minority of an already rare syndrome.
⚖️

Clinical Burden

Moderate
The infectious burden is largely correctable: immunoglobulin replacement produced a dramatic fall in infections in the defining cohort, and unlike CD40L deficiency there is no mortality driver from opportunistic infection or from sclerosing cholangitis — no deaths were attributed to AID deficiency in the Latin American registry. The residual burden is autoimmune and inflammatory disease, which affected roughly a fifth of the European cohort and is not addressed by replacement therapy.
Show evidence (2 references)
PMID:14962793 SUPPORT Human Clinical
"Most patients had suffered from recurrent and severe infections, however, intravenous immunoglobulin (IVIG) replacement therapy resulted in a dramatic decrease in the number of infections."
Establishes that the infectious component of the burden is largely correctable with replacement therapy.
PMID:14962793 SUPPORT Human Clinical
"It is striking to note that six patients developed autoimmune or inflammatory disorders including diabetes mellitus, polyarthritis, autoimmune hepatitis, hemolytic anemia, immune thrombocytopenia, Crohn's disease and chronic uveitis."
Quantifies the autoimmune/inflammatory burden that replacement therapy does not address (6 of 29 patients).
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Hyper-IgM Syndrome Type 2:

Overlapping Features The X-linked CD40LG defect produces the same serum immunoglobulin pattern, and separating the two is the defining diagnostic act in a boy with hyper-IgM. The discriminator is opportunistic infection: CD40L deficiency additionally loses T-cell licensing of macrophages and dendritic cells, so Pneumocystis, Cryptosporidium, and the fungal and opportunistic infections of the registry cohort belong to it, not to AID deficiency, whose defect is B-cell intrinsic. Massive lymphoid hyperplasia points the other way.
Distinguishing Features
  • Opportunistic and fungal infections, neutropenia, and sclerosing cholangitis occur in CD40L deficiency but not in AID deficiency.
  • Germinal-center hyperplasia with marked lymphadenopathy and preserved cell-mediated immunity characterize AID deficiency.
  • Inheritance differs — X-linked for CD40L deficiency, autosomal recessive for AID deficiency.
Show evidence (1 reference)
PMID:24402618 SUPPORT Human Clinical
"Previously undescribed fungal and opportunistic infections were observed in CD40L-deficient patients but not in the two patients with AID deficiency."
The registry states the discriminating observation directly: the opportunistic-infection burden separates CD40L deficiency from AID deficiency.
Hyper-IgM syndrome type 3 (CD40 deficiency) Not Yet Curated MONDO:0011735
Overlapping Features Biallelic CD40 loss is the autosomal recessive phenocopy of CD40L deficiency — the same receptor-ligand axis failing from the B-cell and myeloid side. It shares the opportunistic-infection susceptibility that distinguishes the CD40 axis from AID deficiency, and so sits on the same side of the discriminator.
Distinguishing Features
  • Autosomal recessive like AID deficiency, but with the opportunistic infections of a CD40-axis defect.
  • IUIS places CD40 deficiency in Table 1 (combined immunodeficiency) rather than among the predominantly antibody deficiencies.
{ }

Source YAML

click to show
name: Hyper-IgM Syndrome Type 2
creation_date: "2026-08-29T00:00:00Z"
category: Mendelian
synonyms:
- HIGM2
- AID deficiency
- AICDA deficiency
- Activation-induced cytidine deaminase deficiency
- Immunoglobulin class switch recombination deficiency 1
description: >-
  Hyper-IgM syndrome type 2 (HIGM2) is a primary antibody deficiency caused by
  biallelic loss-of-function variants in AICDA, encoding activation-induced
  cytidine deaminase (AID). AID is a B-cell-restricted cytidine deaminase
  expressed in germinal center B cells that initiates both immunoglobulin
  class-switch recombination (CSR) and somatic hypermutation (SHM) by
  deaminating cytosine residues in immunoglobulin switch and variable regions.
  Its loss therefore abolishes two distinct arms of antigen-driven antibody
  maturation at once: patients cannot switch from IgM to IgG, IgA, or IgE, and
  cannot introduce the mutations that underpin affinity maturation. The serum
  profile is the diagnostic signature — normal or elevated IgM with absent or
  very low IgG, IgA, and IgE, and normal numbers of circulating B cells.
  Clinically this produces recurrent bacterial sinopulmonary and mucosal
  infection from infancy, together with a hallmark massive lymphoid hyperplasia
  (lymphadenopathy and tonsillar enlargement driven by giant germinal centers)
  that is far more prominent than in most other antibody deficiencies. A
  substantial minority develop autoimmune or inflammatory disease, which is now
  understood mechanistically: AID is independently required for the removal of
  developing autoreactive B cells, so its loss breaches both central and
  peripheral B-cell tolerance.

  SCOPE AND CONTRAST. The defect is strictly B-cell intrinsic. This is the key
  distinction from the CD40L (HIGM1) and CD40 (HIGM3) hyper-IgM syndromes,
  where the same CSR block arises from failed T-cell-to-B-cell licensing and
  the same CD40 pathway is additionally required for macrophage and dendritic
  cell activation. Because T-cell and macrophage effector function is intact in
  AID deficiency, HIGM2 patients are not susceptible to the opportunistic
  infections (Pneumocystis, Cryptosporidium, and other fungal or protozoal
  organisms) that define the CD40L/CD40 forms, and hematopoietic cell
  transplantation is correspondingly not a routine indication. The IUIS 2022
  classification records the same split: AID deficiency sits in Table 3
  (predominantly antibody deficiencies) whereas CD40LG and CD40 deficiency sit
  in Table 1 (combined immunodeficiencies). This entry covers the autosomal
  recessive disease as its primary subject; a rarer autosomal dominant form
  caused by heterozygous C-terminal AICDA variants, in which the CSR defect
  occurs with preserved SHM, is curated here as a distinct genetic and
  inheritance context rather than as a separate entry.
disease_term:
  preferred_term: Hyper-IgM Syndrome Type 2
  term:
    id: MONDO:0011528
    label: hyper-IgM syndrome type 2
parents:
- Primary Immunodeficiency
- Antibody Deficiency Disorder
- Hyper-IgM Syndrome
classifications:
  harrisons_chapter:
  - classification_value: IMMUNE_RHEUMATOLOGIC
    notes: >-
      A primary immunodeficiency; Harrison's covers the primary
      immunodeficiency diseases in the immunology/rheumatology Part.
    evidence:
    - reference: PMID:17560278
      reference_title: "Pathophysiology of B-cell intrinsic immunoglobulin class switch recombination deficiencies."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        B-cell intrinsic immunoglobulin class switch recombination (Ig-CSR)
        deficiencies, previously termed hyper-IgM syndromes, are genetically
        determined conditions characterized by normal or elevated serum IgM
        levels and an absence or very low levels of IgG, IgA, and IgE.
      explanation: >-
        Characterizes the hyper-IgM syndromes as genetically determined
        immunodeficiency disorders, placing HIGM2 in the immunologic Part.
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    notes: >-
      Monogenic autosomal recessive disorder of AICDA.
  iuis_category:
    classification_value: predominantly antibody deficiency
    notes: >-
      IUIS 2022 phenotypic classification Table 3 (predominantly antibody
      deficiencies), section 3 "Severe Reduction in Serum IgG and IgA with
      Normal/Elevated IgM and Normal Numbers of B cells, Hyper IgM". Both the
      autosomal recessive and the autosomal dominant AICDA rows sit in this
      section. NOTE THE CONTRAST: the CD40LG and CD40 hyper-IgM syndromes are
      NOT in Table 3 — IUIS 2022 places them in Table 1 (combined
      immunodeficiencies), because the CD40 pathway defect impairs T-cell and
      macrophage activation as well as B-cell class switching. Curating
      "hyper-IgM syndrome" as a single disease would therefore straddle two
      IUIS tables. The AICDA recessive row in the source PDF is corrupted by
      text extraction — its disease label was lifted onto a later line and its
      OMIM is misprinted as a 7-digit "6055258" (the correct identifier is
      OMIM:605258, confirmed against MONDO:0011528) — so the section heading
      and the label line are quoted here instead of the recessive row itself.
    evidence:
    - reference: PMID:35748970
      reference_title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "3. Severe Reduction in Serum IgG and IgA with Normal/Elevated IgM and Normal Numbers of B cells, Hyper IgM"
      explanation: >-
        The section-3 heading of IUIS 2022 Table 3, the table of predominantly
        antibody deficiencies, defines the hyper-IgM section that contains the
        two AICDA rows ("AID deficiency AICDA", recessive and dominant). The
        heading is quoted rather than the recessive row itself because that row
        is corrupted in the source PDF (see notes).
inheritance:
- name: Autosomal recessive inheritance
  description: >-
    The classic form of HIGM2 is inherited as an autosomal recessive trait,
    caused by mutations affecting both AICDA alleles.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:11007475
    reference_title: "Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We herein report mutations in the human counterpart of AID in patients
      with the autosomal recessive form of hyper-IgM syndrome (HIGM2).
    explanation: >-
      The gene-discovery study establishes AICDA mutations as the cause of the
      autosomal recessive form of hyper-IgM syndrome.
  - reference: PMID:15893695
    reference_title: "Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autosomal recessive form of hyper-IgM syndrome type 2 (AR-HIGM2) is
      secondary to mutations affecting both alleles of AICDA gene encoding
      activation-induced cytidine deaminase
    explanation: >-
      Confirms that the recessive disease requires mutation of both AICDA
      alleles.
- name: Autosomal dominant inheritance
  description: >-
    A rarer autosomal dominant form (AD-HIGM2) is caused by heterozygous
    variants affecting the C-terminal region of AID, classically the R190X
    nonsense variant. The C-terminus is required for the DNA-repair steps
    specific to class-switch recombination but not for somatic hypermutation,
    so these patients have a variable CSR defect with preserved SHM. IUIS 2022
    Table 3 lists this dominant AICDA form as its own row (OMIM 605257)
    alongside the recessive row, and records that the causal variants localise
    uniquely to the nuclear export signal; those row fragments are too short
    and too corrupted by PDF text extraction to quote as standalone evidence,
    so the published patient series are cited instead.
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:15893695
    reference_title: "Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Variable defect in in vivo CSR inherited as an autosomal dominant (AD)
      trait strongly suggests that this heterozygous AICDA mutation causes
      HIGM (AD-HIGM2).
    explanation: >-
      Establishes a dominantly inherited form of HIGM2 caused by a single
      heterozygous AICDA variant.
  - reference: PMID:32423680
    reference_title: "From Dysgammaglobulinemia to Autosomal-Dominant Activation-Induced Cytidine Deaminase Deficiency: Unraveling an Inherited Immunodeficiency after 50 Years."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The genetic investigation of a family presenting with a dominant form of
      hyper IgM syndrome published in 1963 and 1975 revealed a R190X nonsense
      mutation in activation-induced cytidine deaminase.
    explanation: >-
      An independent kindred with dominantly inherited hyper-IgM syndrome
      resolved to a heterozygous R190X AICDA variant.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    No population-based prevalence estimate for HIGM2 has been published. The
    disease is known from small international case series: the largest
    dedicated cohort assembled 29 patients from 22 families across multiple
    European and Middle Eastern referral centres. Registry data give a sense of
    its rarity relative to the CD40L form — in the Latin American HIGM registry
    only 2 of 37 molecularly defined hyper-IgM patients had AID deficiency,
    against 35 with CD40L deficiency. Both figures are referral-based counts,
    not denominators, so no rate per 100,000 is asserted here.
  evidence:
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We retrospectively analyzed clinical, immunologic and genetic
      characteristics of 29 patients from 22 families with AID deficiency.
    explanation: >-
      The largest dedicated AID-deficiency cohort comprises 29 patients from 22
      families worldwide, consistent with an ultra-rare disease reported as
      case series rather than population rates.
  - reference: PMID:24402618
    reference_title: "First report of the Hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CD40 ligand (CD40L) deficiency was found in 35 patients from 25 families
      and activation-induced cytidine deaminase (AID) deficiency in 2 unrelated
      patients.
    explanation: >-
      In a multinational hyper-IgM registry AID deficiency accounted for only 2
      of 37 genetically defined patients, indicating it is a small minority of
      an already rare syndrome.
pathophysiology:
- name: AID Enzymatic Loss of Function
  conforms_to: "germinal_center_reaction#Germinal Center Reaction"
  biological_scale: MOLECULAR
  description: >-
    Activation-induced cytidine deaminase is a member of the cytidine deaminase
    family whose expression is restricted to germinal center B cells. It
    initiates antibody diversification by deaminating cytosine to uracil in
    single-stranded DNA at the immunoglobulin switch and variable regions,
    creating the U:G mismatches that downstream repair pathways convert into
    either switch-region double-strand breaks or point mutations. Biallelic
    loss-of-function AICDA variants abolish this enzymatic activity, removing
    the single upstream trigger for both antibody-diversification programs.
    Anchors the module's conformance here rather than on either downstream
    node (Failed Immunoglobulin Class-Switch Recombination, Failed Somatic
    Hypermutation) because this is the molecular lesion that causes both of
    them: neither downstream node alone covers the module's bundled
    "Germinal Center Reaction" claim, but this one node, read alongside its
    two direct downstream edges, does.
  cell_types:
  - preferred_term: Germinal center B cell
    term:
      id: CL:0000844
      label: germinal center B cell
  molecular_functions:
  - preferred_term: cytidine deaminase activity
    term:
      id: GO:0004126
      label: cytidine deaminase activity
    modifier: LOSS_OF_FUNCTION
  biological_processes:
  - preferred_term: Somatic Hypermutation of Immunoglobulin Genes
    term:
      id: GO:0016446
      label: somatic hypermutation of immunoglobulin genes
    modifier: ABSENT
  - preferred_term: Class Switch Recombination
    term:
      id: GO:0045190
      label: isotype switching
    modifier: ABSENT
  evidence:
  - reference: PMID:11007475
    reference_title: "Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The activation-induced cytidine deaminase (AID) gene, specifically
      expressed in germinal center B cells in mice, is a member of the cytidine
      deaminase family.
    explanation: >-
      Identifies AID as a germinal-center-B-cell-restricted cytidine deaminase,
      grounding the enzymatic activity and cell type of this node.
  downstream:
  - target: Failed Immunoglobulin Class-Switch Recombination
    causal_link_type: DIRECT
    description: >-
      Without AID-mediated deamination of switch regions, the DNA lesions that
      initiate class-switch recombination are never generated.
    evidence:
    - reference: PMID:11007475
      reference_title: "Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Three major abnormalities characterize AID deficiency: (1) the absence
        of immunoglobulin class switch recombination
      explanation: >-
        Absence of class-switch recombination is listed as the first cardinal
        abnormality caused by AID deficiency.
  - target: Failed Somatic Hypermutation
    causal_link_type: DIRECT
    description: >-
      The same deamination step seeds the point mutations of somatic
      hypermutation in immunoglobulin variable regions, so SHM fails in
      parallel with CSR rather than as a consequence of it.
    evidence:
    - reference: PMID:11007475
      reference_title: "Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "(2) the lack of immunoglobulin somatic hypermutations"
      explanation: >-
        Lack of somatic hypermutation is the second cardinal abnormality of AID
        deficiency, establishing it as a parallel consequence of enzyme loss.
- name: Failed Immunoglobulin Class-Switch Recombination
  biological_scale: MOLECULAR
  description: >-
    Class-switch recombination replaces the IgM/IgD constant region with a
    downstream constant region, converting a naive B cell's output to IgG, IgA,
    or IgE without altering antigen specificity. In AID deficiency this
    recombination does not occur. The block is B-cell intrinsic: germline
    switch transcripts are still produced and the upstream T-cell help signal
    is intact, so the lesion lies at the DNA-modification step itself.
  cell_types:
  - preferred_term: Germinal center B cell
    term:
      id: CL:0000844
      label: germinal center B cell
  biological_processes:
  - preferred_term: Immunoglobulin isotype switching
    term:
      id: GO:0045190
      label: isotype switching
    modifier: LOSS_OF_FUNCTION
  evidence:
  - reference: PMID:11007474
    reference_title: "Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      AID-/- spleen cells stimulated in vitro with LPS and cytokines failed to
      undergo class switch recombination although they expressed germline
      transcripts.
    explanation: >-
      The AID-knockout mouse shows the switch block is at the recombination
      step itself, downstream of germline transcription — evidence from a model
      organism that defines where in the pathway the lesion sits.
  - reference: PMID:17560278
    reference_title: "Pathophysiology of B-cell intrinsic immunoglobulin class switch recombination deficiencies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      the description of the activation-induced cytidine deaminase (AID)
      deficiency (Ig-CSR deficiency 1), caused by recessive mutations of AICDA
      gene, characterized by a defect in CSR and SHM
    explanation: >-
      A review of the CSR deficiencies characterizes recessive AICDA mutation
      as producing a combined CSR and SHM defect.
  downstream:
  - target: IgM-Restricted Antibody Repertoire
    causal_link_type: DIRECT
    description: >-
      With switching blocked, plasma cells can only secrete the IgM isotype
      encoded by the unrearranged constant region.
    evidence:
    - reference: PMID:17560278
      reference_title: "Pathophysiology of B-cell intrinsic immunoglobulin class switch recombination deficiencies."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        characterized by normal or elevated serum IgM levels and an absence or
        very low levels of IgG, IgA, and IgE
      explanation: >-
        The failure to switch produces exactly this serum profile — retained
        IgM with loss of the switched isotypes.
  - target: Giant Germinal Center Formation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      B cells that cannot complete the switching program continue to be
      stimulated and re-enter the germinal center reaction instead of exiting
      it as switched memory or plasma cells, so germinal centers enlarge rather
      than resolve.
    evidence:
    - reference: PMID:11007474
      reference_title: "Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        AID deficiency caused a complete defect in class switching and showed a
        hyper-IgM phenotype with enlarged germinal centers containing strongly
        activated B cells before or after immunization.
      explanation: >-
        In AID-deficient mice the switching defect is accompanied by enlarged
        germinal centers holding strongly activated B cells, linking the failed
        switch to germinal-center overgrowth.
- name: Failed Somatic Hypermutation
  biological_scale: MOLECULAR
  description: >-
    Somatic hypermutation introduces point mutations into immunoglobulin
    variable-region genes, generating the sequence variation on which
    affinity-based selection acts in the germinal center. AID deficiency
    abolishes it. Memory B cells are still generated in normal numbers but
    carry unmutated variable regions. This arm is independent of the CSR arm:
    C-terminal AICDA variants can spare it while still blocking CSR.
  cell_types:
  - preferred_term: Germinal center B cell
    term:
      id: CL:0000844
      label: germinal center B cell
  - preferred_term: Memory B cell
    term:
      id: CL:0000787
      label: memory B cell
  biological_processes:
  - preferred_term: Somatic hypermutation of immunoglobulin genes
    term:
      id: GO:0016446
      label: somatic hypermutation of immunoglobulin genes
    modifier: LOSS_OF_FUNCTION
  evidence:
  - reference: PMID:35748970
    reference_title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "memory B cells but lacking"
    explanation: >-
      The IUIS Table 3 immunologic column for the recessive AICDA row records
      normal memory B cells that nonetheless lack somatic hypermutation.
  - reference: PMID:11007474
    reference_title: "Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Immunization of AID-/- chimera with 4-hydroxy-3-nitrophenylacetyl (NP)
      chicken gamma-globulin induced neither accumulation of mutations in the
      NP-specific variable region gene nor class switching.
    explanation: >-
      Antigen challenge of AID-deficient mice produced no variable-region
      mutation, demonstrating that AID is required for somatic hypermutation
      in vivo.
  downstream:
  - target: Absent Affinity Maturation
    causal_link_type: DIRECT
    description: >-
      Without variable-region mutation there is no sequence variation for
      germinal-center selection to act on, so antibody affinity cannot improve
      with successive antigen exposure.
    evidence:
    - reference: PMID:11007475
      reference_title: "Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        demonstrates the absolute requirement for AID in several crucial steps
        of B cell terminal differentiation necessary for efficient antibody
        responses
      explanation: >-
        AID is required for the terminal B-cell differentiation steps that
        produce efficient antibody responses, of which affinity maturation is
        one.
  - target: Breakdown of B-Cell Self-Tolerance
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Beyond diversification, AID is separately required to purge developing
      autoreactive B cells. Its loss leaves an abnormal repertoire enriched for
      self-reactive specificities at both the central and peripheral tolerance
      checkpoints.
    evidence:
    - reference: PMID:21700883
      reference_title: "Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        New emigrant/transitional and mature naive B cells from AID-deficient
        patients express an abnormal Ig repertoire and high frequencies of
        autoreactive antibodies, demonstrating that AID is required for the
        establishment of both central and peripheral B-cell tolerance.
      explanation: >-
        Single-cell antibody cloning from AID-deficient patients shows loss of
        both tolerance checkpoints, linking the enzyme defect to autoreactivity.
- name: IgM-Restricted Antibody Repertoire
  biological_scale: ORGANISM
  description: >-
    The systemic consequence of the switching block is a humoral compartment
    that produces only IgM. Serum IgM is normal or elevated — partly because
    unswitched B cells continue to be driven by antigen — while IgG, IgA, and
    IgE are absent or very low. Circulating B-cell numbers are normal, which
    distinguishes HIGM2 from the agammaglobulinemias, where the lesion is a
    developmental block upstream of B-cell egress.
  cell_types:
  - preferred_term: Plasma cell
    term:
      id: CL:0000786
      label: plasma cell
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  biological_processes:
  - preferred_term: Immunoglobulin production
    term:
      id: GO:0002377
      label: immunoglobulin production
    modifier: DECREASED
  evidence:
  - reference: PMID:35748970
    reference_title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "3. Severe Reduction in Serum IgG and IgA with Normal/Elevated IgM and Normal Numbers of B cells, Hyper IgM"
    explanation: >-
      The IUIS section heading defining this disease group states the exact
      composition of this node: severely reduced IgG and IgA, normal or
      elevated IgM, and normal numbers of circulating B cells.
  - reference: PMID:36931691
    reference_title: "Type 2 hyper-IgM syndrome with a rare variant of AICDA gene mutation in a young woman."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Blood investigations revealed increased IgM levels with reduced IgG, IgA
      and IgE levels.
    explanation: >-
      A genetically confirmed HIGM2 patient shows the characteristic isotype
      profile of raised IgM with all three switched isotypes reduced.
  downstream:
  - target: Loss of Opsonizing and Mucosal Antibody Function
    causal_link_type: DIRECT
    description: >-
      IgM is a poor opsonin relative to IgG and cannot be transported across
      mucosal epithelium in place of secretory IgA, so an IgM-only repertoire
      cannot perform the effector functions those isotypes provide.
    evidence:
    - reference: PMID:17560278
      reference_title: "Pathophysiology of B-cell intrinsic immunoglobulin class switch recombination deficiencies."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        CSR and SHM, the major events of antigen-triggered antibody maturation
      explanation: >-
        CSR and SHM are identified as the major events of antibody maturation,
        so losing both leaves antibody function immature and ineffective.
- name: Absent Affinity Maturation
  biological_scale: CELLULAR
  description: >-
    Memory B cells are produced but their variable regions remain in germline
    configuration, so the antibody repertoire never improves in affinity across
    repeated antigen encounters. Secondary responses are therefore no better
    than primary ones, compounding the isotype deficit.
  cell_types:
  - preferred_term: Memory B cell
    term:
      id: CL:0000787
      label: memory B cell
  biological_processes:
  - preferred_term: Somatic hypermutation of immunoglobulin genes
    term:
      id: GO:0016446
      label: somatic hypermutation of immunoglobulin genes
    modifier: LOSS_OF_FUNCTION
  evidence:
  - reference: PMID:11007475
    reference_title: "Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The phenotype observed in HIGM2 patients (and in AID-/- mice)
      demonstrates the absolute requirement for AID in several crucial steps of
      B cell terminal differentiation necessary for efficient antibody
      responses.
    explanation: >-
      AID is required for the terminal B-cell differentiation steps underlying
      efficient antibody responses; affinity maturation is the step this node
      represents.
  downstream:
  - target: Loss of Opsonizing and Mucosal Antibody Function
    causal_link_type: DIRECT
    description: >-
      Low-affinity germline-encoded antibody binds pathogens poorly, further
      degrading the protective quality of the residual IgM response.
- name: Loss of Opsonizing and Mucosal Antibody Function
  biological_scale: ORGANISM
  description: >-
    The two arms converge here. The patient retains antibody, but it is of the
    wrong isotype and of germline affinity: no IgG to opsonize encapsulated
    bacteria and fix complement efficiently in tissue, no secretory IgA to
    exclude organisms at respiratory and gastrointestinal mucosal surfaces, and
    no affinity-matured binding to compensate. Humoral protection against
    extracellular bacteria is therefore lost, while cellular immunity is
    untouched.
  biological_processes:
  - preferred_term: Complement activation and opsonization by antibody
    term:
      id: GO:0006956
      label: complement activation
    modifier: DECREASED
  evidence:
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most patients had suffered from recurrent and severe infections, however,
      intravenous immunoglobulin (IVIG) replacement therapy resulted in a
      dramatic decrease in the number of infections.
    explanation: >-
      That replacing IgG largely abolishes the infections demonstrates the
      infections are caused by the missing antibody function rather than by any
      cellular defect.
  downstream:
  - target: Recurrent Bacterial Sinopulmonary and Mucosal Infection
    causal_link_type: DIRECT
    description: >-
      Absent opsonizing and mucosal antibody permits recurrent infection by
      extracellular and encapsulated bacteria at respiratory and
      gastrointestinal surfaces.
    evidence:
    - reference: PMID:35748970
      reference_title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Bacterial infections, enlarged lymph nodes and"
      explanation: >-
        The IUIS Table 3 associated-features column for AID deficiency lists
        bacterial infections as the cardinal clinical consequence.
- name: Recurrent Bacterial Sinopulmonary and Mucosal Infection
  biological_scale: ORGANISM
  description: >-
    Clinically the infections are bacterial and mucosal — recurrent sinusitis,
    otitis media, and pneumonia progressing to bronchiectasis, with
    gastrointestinal involvement. The spectrum is narrower than in the
    CD40L/CD40 hyper-IgM syndromes: because AID acts only in B cells and leaves
    T-cell and macrophage effector function intact, HIGM2 patients do not show
    the Pneumocystis, Cryptosporidium, and other opportunistic infections that
    characterize the CD40 pathway defects. Immunoglobulin replacement markedly
    reduces infection frequency.
  evidence:
  - reference: PMID:24402618
    reference_title: "First report of the Hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Previously undescribed fungal and opportunistic infections were observed
      in CD40L-deficient patients but not in the two patients with AID
      deficiency.
    explanation: >-
      Direct within-registry comparison showing opportunistic and fungal
      infections occurred in the CD40L form but not in AID deficiency — the
      clinical signature of a B-cell-intrinsic rather than combined defect.
  - reference: PMID:36931691
    reference_title: "Type 2 hyper-IgM syndrome with a rare variant of AICDA gene mutation in a young woman."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Radiological imaging of the chest revealed bilateral bronchiectasis.
    explanation: >-
      Illustrates the end-organ consequence of untreated recurrent
      sinopulmonary bacterial infection in a genetically confirmed HIGM2
      patient.
- name: Giant Germinal Center Formation
  biological_scale: TISSUE
  description: >-
    The histological hallmark of AID deficiency. B cells that cannot complete
    the diversification program are repeatedly restimulated and re-enter the
    germinal center rather than exiting as switched or affinity-matured
    progeny. Germinal centers consequently become greatly enlarged and are
    packed with strongly activated B cells — the "giant germinal centers"
    described in the original report and reproduced in AID-null mice.
  cell_types:
  - preferred_term: Germinal center B cell
    term:
      id: CL:0000844
      label: germinal center B cell
  biological_processes:
  - preferred_term: Germinal center formation
    term:
      id: GO:0002467
      label: germinal center formation
    modifier: INCREASED
  evidence:
  - reference: PMID:11007475
    reference_title: "Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      lymph node hyperplasia caused by the presence of giant germinal centers
    explanation: >-
      Names giant germinal centers as the third cardinal abnormality of AID
      deficiency and as the cause of the lymph node hyperplasia.
  downstream:
  - target: Massive Lymphoid Hyperplasia
    causal_link_type: DIRECT
    description: >-
      Enlargement of germinal centers throughout secondary lymphoid tissue
      produces clinically apparent lymph node and tonsillar enlargement.
    evidence:
    - reference: PMID:11007475
      reference_title: "Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        lymph node hyperplasia caused by the presence of giant germinal centers
      explanation: >-
        States the causal relation directly: the giant germinal centers are
        what produce the lymph node hyperplasia.
- name: Massive Lymphoid Hyperplasia
  biological_scale: ORGANISM
  description: >-
    Generalized enlargement of secondary lymphoid tissue — lymphadenopathy and
    tonsillar enlargement — is present in the majority of patients and is
    disproportionate to that seen in other primary antibody deficiencies. It
    can regress on immunoglobulin replacement but persists in a minority.
  evidence:
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Lymphoid hyperplasia developed in 22 patients and persisted in 7 at last
      follow-up.
    explanation: >-
      Quantifies lymphoid hyperplasia in 22 of the 29-patient cohort, and shows
      that it resolves in most but persists in some.
- name: Breakdown of B-Cell Self-Tolerance
  biological_scale: CELLULAR
  description: >-
    AID has a role in B-cell tolerance that is separable from its
    diversification role. In AID-deficient patients both the central checkpoint
    (new emigrant/transitional B cells) and the peripheral checkpoint (mature
    naive B cells) fail to remove autoreactive clones, and anti-nuclear IgM is
    detectable in serum. This provides the mechanistic explanation for the
    autoimmunity seen in a disease that is otherwise one of immune deficiency.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  biological_processes:
  - preferred_term: B cell tolerance induction
    term:
      id: GO:0002514
      label: B cell tolerance induction
    modifier: LOSS_OF_FUNCTION
  evidence:
  - reference: PMID:21700883
    reference_title: "Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      B-cell tolerance was further breached in AID-deficient patients as
      illustrated by the detection of anti-nuclear IgM antibodies in the serum
      of all patients.
    explanation: >-
      Anti-nuclear IgM in all patients tested demonstrates a breached tolerance
      checkpoint in human AID deficiency.
  downstream:
  - target: Autoimmune and Inflammatory Disease
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Retained autoreactive B-cell clones provide the substrate from which
      clinical autoimmune and inflammatory disease develops in a substantial
      minority of patients.
    evidence:
    - reference: PMID:21700883
      reference_title: "Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        patients with hyper-IgM syndromes who are deficient in
        activation-induced cytidine deaminase (AID), which is required for
        class-switch recombination and somatic hypermutation, are prone to
        develop autoimmune diseases
      explanation: >-
        Links AID deficiency to a predisposition to clinical autoimmune disease.
- name: Autoimmune and Inflammatory Disease
  biological_scale: ORGANISM
  description: >-
    A substantial minority of AID-deficient patients develop autoimmune or
    inflammatory disease. The reported spectrum is broad and not confined to
    one organ — autoimmune cytopenias (hemolytic anemia, immune
    thrombocytopenia), polyarthritis, autoimmune hepatitis, type 1 diabetes,
    Crohn's disease, and chronic uveitis have all been described in a single
    cohort.
  evidence:
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is striking to note that six patients developed autoimmune or
      inflammatory disorders including diabetes mellitus, polyarthritis,
      autoimmune hepatitis, hemolytic anemia, immune thrombocytopenia, Crohn's
      disease and chronic uveitis.
    explanation: >-
      Six of 29 cohort patients developed autoimmune or inflammatory disease,
      establishing both the frequency band and the organ spectrum.
phenotypes:
- name: Recurrent Bacterial Infections
  category: Immunologic
  frequency: VERY_FREQUENT
  description: >-
    Recurrent and often severe bacterial infection from early childhood is the
    presenting feature in most patients.
  phenotype_term:
    preferred_term: Recurrent bacterial infections
    term:
      id: HP:0002718
      label: Recurrent bacterial infections
  evidence:
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most patients had suffered from recurrent and severe infections
    explanation: >-
      "Most patients" in the 29-patient cohort supports the VERY_FREQUENT band
      for recurrent infection.
  - reference: PMID:35748970
    reference_title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Bacterial infections, enlarged lymph nodes and"
    explanation: >-
      IUIS lists bacterial infection as the leading associated feature of AID
      deficiency.
- name: Lymphoid Hyperplasia
  category: Immunologic
  frequency: FREQUENT
  description: >-
    Generalized enlargement of secondary lymphoid tissue caused by giant
    germinal centers; developed in 22 of 29 patients (76%) in the largest
    cohort.
  phenotype_term:
    preferred_term: Lymphoid hyperplasia
    term:
      id: HP:0034839
      label: Lymphoid hyperplasia
  evidence:
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Lymphoid hyperplasia developed in 22 patients and persisted in 7 at last
      follow-up.
    explanation: >-
      22 of 29 patients (76%) developed lymphoid hyperplasia, placing it in the
      FREQUENT band (30-79%).
- name: Lymphadenopathy
  category: Immunologic
  description: >-
    Enlarged lymph nodes containing giant germinal centers, a hallmark finding
    that distinguishes HIGM2 from most other primary antibody deficiencies.
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
  evidence:
  - reference: PMID:11007475
    reference_title: "Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      lymph node hyperplasia caused by the presence of giant germinal centers
    explanation: >-
      Lymph node hyperplasia from giant germinal centers is one of the three
      cardinal abnormalities of AID deficiency.
  - reference: PMID:35748970
    reference_title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Bacterial infections, enlarged lymph nodes and"
    explanation: >-
      The IUIS Table 3 associated-features column for AID deficiency lists
      enlarged lymph nodes alongside bacterial infections.
- name: Enlarged Tonsils
  category: Immunologic
  description: >-
    Tonsillar enlargement is part of the same lymphoid hyperplasia and is often
    apparent on physical examination.
  phenotype_term:
    preferred_term: Enlarged tonsils
    term:
      id: HP:0030812
      label: Enlarged tonsils
  evidence:
  - reference: PMID:36931691
    reference_title: "Type 2 hyper-IgM syndrome with a rare variant of AICDA gene mutation in a young woman."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      bilateral purulent ear discharge since childhood with tonsillar
      enlargement on examination
    explanation: >-
      Tonsillar enlargement was an examination finding in a genetically
      confirmed HIGM2 patient. A single case report, so no frequency band is
      asserted.
- name: Increased Circulating IgM
  category: Immunologic
  frequency: VERY_FREQUENT
  description: >-
    Normal or elevated serum IgM alongside absent switched isotypes is the
    defining laboratory signature of the hyper-IgM syndromes.
  phenotype_term:
    preferred_term: Increased circulating IgM level
    term:
      id: HP:0003496
      label: Increased circulating IgM level
  evidence:
  - reference: PMID:17560278
    reference_title: "Pathophysiology of B-cell intrinsic immunoglobulin class switch recombination deficiencies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      characterized by normal or elevated serum IgM levels and an absence or
      very low levels of IgG, IgA, and IgE
    explanation: >-
      Normal-to-elevated IgM is definitional for this disease group, supporting
      the VERY_FREQUENT band.
- name: Decreased Circulating IgG
  category: Immunologic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Decreased circulating IgG concentration
    term:
      id: HP:0004315
      label: Decreased circulating IgG concentration
  evidence:
  - reference: PMID:17560278
    reference_title: "Pathophysiology of B-cell intrinsic immunoglobulin class switch recombination deficiencies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      an absence or very low levels of IgG, IgA, and IgE
    explanation: >-
      Absent or very low IgG is definitional for the Ig-CSR deficiencies,
      supporting the VERY_FREQUENT band.
- name: Decreased Circulating IgA
  category: Immunologic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Decreased circulating IgA concentration
    term:
      id: HP:0002720
      label: Decreased circulating IgA concentration
  evidence:
  - reference: PMID:17560278
    reference_title: "Pathophysiology of B-cell intrinsic immunoglobulin class switch recombination deficiencies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      an absence or very low levels of IgG, IgA, and IgE
    explanation: >-
      Absent or very low IgA is definitional for the Ig-CSR deficiencies,
      supporting the VERY_FREQUENT band.
- name: Autoimmune and Inflammatory Manifestations
  category: Immunologic
  frequency: OCCASIONAL
  description: >-
    Autoimmune or inflammatory disease developed in 6 of 29 patients (21%) in
    the largest cohort, spanning autoimmune cytopenias, polyarthritis,
    autoimmune hepatitis, diabetes mellitus, Crohn's disease, and uveitis.
  phenotype_term:
    preferred_term: Autoimmune and inflammatory disease
    term:
      id: HP:0002960
      label: Autoimmunity
  evidence:
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is striking to note that six patients developed autoimmune or
      inflammatory disorders including diabetes mellitus, polyarthritis,
      autoimmune hepatitis, hemolytic anemia, immune thrombocytopenia, Crohn's
      disease and chronic uveitis.
    explanation: >-
      6 of 29 patients (21%) is within the OCCASIONAL band (5-29%), and the
      sentence enumerates the organ spectrum.
- name: Autoimmune Hemolytic Anemia
  category: Hematologic
  description: >-
    One of the autoimmune cytopenias reported in AID deficiency.
  phenotype_term:
    preferred_term: Autoimmune hemolytic anemia
    term:
      id: HP:0001890
      label: Autoimmune hemolytic anemia
  evidence:
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is striking to note that six patients developed autoimmune or
      inflammatory disorders including diabetes mellitus, polyarthritis,
      autoimmune hepatitis, hemolytic anemia, immune thrombocytopenia, Crohn's
      disease and chronic uveitis.
    explanation: >-
      Hemolytic anemia is named among the autoimmune disorders occurring in the
      cohort. The six affected patients span seven listed conditions, so
      individual manifestations were reported in only one or two patients each
      and no per-manifestation frequency band is asserted.
- name: Autoimmune Thrombocytopenia
  category: Hematologic
  description: >-
    Immune thrombocytopenia reported among the autoimmune complications.
  phenotype_term:
    preferred_term: Autoimmune thrombocytopenia
    term:
      id: HP:0001973
      label: Autoimmune thrombocytopenia
  evidence:
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is striking to note that six patients developed autoimmune or
      inflammatory disorders including diabetes mellitus, polyarthritis,
      autoimmune hepatitis, hemolytic anemia, immune thrombocytopenia, Crohn's
      disease and chronic uveitis.
    explanation: >-
      Immune thrombocytopenia is named among the autoimmune disorders in the
      cohort. Reported in one or two patients, so no frequency band is
      asserted.
- name: Arthritis
  category: Musculoskeletal
  description: >-
    Polyarthritis reported among the inflammatory complications.
  phenotype_term:
    preferred_term: Polyarthritis
    term:
      id: HP:0001369
      label: Arthritis
  evidence:
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is striking to note that six patients developed autoimmune or
      inflammatory disorders including diabetes mellitus, polyarthritis,
      autoimmune hepatitis, hemolytic anemia, immune thrombocytopenia, Crohn's
      disease and chronic uveitis.
    explanation: >-
      Polyarthritis is named among the autoimmune and inflammatory disorders in
      the cohort. Reported in one or two patients, so no frequency band is
      asserted.
- name: Autoimmune Hepatitis
  category: Gastrointestinal
  description: >-
    Autoimmune hepatitis reported among the autoimmune complications.
  phenotype_term:
    preferred_term: Autoimmune hepatitis
    term:
      id: HP:5210421
      label: Autoimmune hepatitis
  evidence:
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is striking to note that six patients developed autoimmune or
      inflammatory disorders including diabetes mellitus, polyarthritis,
      autoimmune hepatitis, hemolytic anemia, immune thrombocytopenia, Crohn's
      disease and chronic uveitis.
    explanation: >-
      Autoimmune hepatitis is named among the autoimmune disorders in the
      cohort. Reported in one or two patients, so no frequency band is
      asserted.
- name: Crohn's Disease
  category: Gastrointestinal
  description: >-
    Inflammatory bowel disease of Crohn type reported among the inflammatory
    complications, representing the gastrointestinal arm of the immune
    dysregulation.
  phenotype_term:
    preferred_term: Crohn's disease
    term:
      id: HP:0100280
      label: Crohn's disease
  evidence:
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      immune thrombocytopenia, Crohn's disease and chronic uveitis
    explanation: >-
      Crohn's disease is named among the inflammatory disorders in the cohort.
- name: Bronchiectasis
  category: Respiratory
  description: >-
    Structural airway damage resulting from repeated untreated bacterial
    sinopulmonary infection.
  phenotype_term:
    preferred_term: Bronchiectasis
    term:
      id: HP:0002110
      label: Bronchiectasis
  evidence:
  - reference: PMID:36931691
    reference_title: "Type 2 hyper-IgM syndrome with a rare variant of AICDA gene mutation in a young woman."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Radiological imaging of the chest revealed bilateral bronchiectasis.
    explanation: >-
      Bilateral bronchiectasis in a genetically confirmed HIGM2 patient. Single
      case report, so no frequency band is asserted.
- name: Otitis Media
  category: Otolaryngologic
  description: >-
    Chronic suppurative otitis media as part of the recurrent bacterial
    mucosal infection burden.
  phenotype_term:
    preferred_term: Chronic suppurative otitis media
    term:
      id: HP:0000388
      label: Otitis media
  evidence:
  - reference: PMID:36931691
    reference_title: "Type 2 hyper-IgM syndrome with a rare variant of AICDA gene mutation in a young woman."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Otoscopic examination showed features suggestive of chronic suppurative
      otitis media.
    explanation: >-
      Chronic suppurative otitis media in a genetically confirmed HIGM2
      patient.
genetic:
- name: AICDA
  notes: >-
    AICDA encodes activation-induced cytidine deaminase. Biallelic
    loss-of-function variants cause the classic autosomal recessive HIGM2, with
    combined loss of class-switch recombination and somatic hypermutation.
    Fifteen distinct mutations were identified in the largest cohort with no
    significant genotype-phenotype correlation.
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  gene_term:
    preferred_term: AICDA
    term:
      id: hgnc:13203
      label: AICDA
  association: Causative
  evidence:
  - reference: PMID:11007475
    reference_title: "Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We herein report mutations in the human counterpart of AID in patients
      with the autosomal recessive form of hyper-IgM syndrome (HIGM2).
    explanation: >-
      The gene-discovery study identifying AICDA mutations as causative for
      HIGM2.
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fifteen distinct AID mutations were found but there was no significant
      genotype-phenotype correlation.
    explanation: >-
      Documents allelic heterogeneity at AICDA without a genotype-phenotype
      correlation.
- name: AICDA C-terminal heterozygous variants (autosomal dominant HIGM2)
  notes: >-
    Heterozygous nonsense variants affecting the C-terminal region of AID —
    classically R190X, which disrupts the nuclear export signal — cause a
    dominantly inherited form of HIGM2. The C-terminus is dispensable for the
    deaminase activity that drives somatic hypermutation but required for the
    DNA-repair steps specific to class-switch recombination, so these patients
    have a CSR-only defect with preserved SHM. Switch-region double-strand
    breaks are still generated, placing the block downstream of the breaks
    rather than at their creation. This is curated as a distinct genetic
    context of the same disease rather than a separate entry.
  gene_term:
    preferred_term: AICDA
    term:
      id: hgnc:13203
      label: AICDA
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  variants:
  - name: AICDA R190X
    type: nonsense
    description: >-
      Heterozygous C-terminal nonsense variant removing the AID nuclear export
      signal. Causes a class-switch-recombination defect with preserved somatic
      hypermutation, inherited as an autosomal dominant trait.
    gene:
      preferred_term: AICDA
      term:
        id: hgnc:13203
        label: AICDA
    evidence:
    - reference: PMID:15893695
      reference_title: "Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We herein report the immunological phenotype of seven patients carrying
        a single heterozygous R190X mutation in AICDA.
      explanation: >-
        Identifies R190X as the recurrent heterozygous AICDA variant underlying
        the dominant form, in a series of seven patients.
  evidence:
  - reference: PMID:15893695
    reference_title: "Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We herein report the immunological phenotype of seven patients carrying a
      single heterozygous R190X mutation in AICDA.
    explanation: >-
      Seven patients with a single heterozygous R190X AICDA variant define the
      dominant form.
  - reference: PMID:15893695
    reference_title: "Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The characteristics of the AD-HIGM2 phenotype indicate that the AID
      C-terminal region may be involved in DNA repair machinery required for
      CSR.
    explanation: >-
      Attributes the CSR-selective defect to loss of a C-terminal DNA-repair
      function, the mechanistic basis of this genetic context.
  - reference: PMID:32423680
    reference_title: "From Dysgammaglobulinemia to Autosomal-Dominant Activation-Induced Cytidine Deaminase Deficiency: Unraveling an Inherited Immunodeficiency after 50 Years."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The genetic investigation of a family presenting with a dominant form of
      hyper IgM syndrome published in 1963 and 1975 revealed a R190X nonsense
      mutation in activation-induced cytidine deaminase.
    explanation: >-
      Independent confirmation that R190X underlies a dominantly inherited
      hyper-IgM syndrome, in a family followed for six decades.
diagnosis:
- name: Immunoglobulin panel showing the hyper-IgM pattern
  description: >-
    The entry point is the serum immunoglobulin profile shared by every
    hyper-IgM syndrome: normal or elevated IgM with absent or decreased IgG,
    IgA and IgE. This identifies the syndrome but not the gene, which is why
    molecular testing follows.
  diagnosis_term:
    preferred_term: serum immunoglobulin measurement
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  evidence:
  - reference: PMID:24402618
    reference_title: "First report of the Hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hyper-IgM (HIGM) syndrome is a heterogeneous group of disorders characterized by normal or elevated serum IgM levels associated with absent or decreased IgG, IgA and IgE."
    explanation: >-
      States the laboratory pattern that defines the clinical phenotype before
      the causal gene is known.
- name: Molecular genetic testing of AICDA
  description: >-
    Because the hyper-IgM laboratory pattern is shared across genes, the
    diagnosis of AID deficiency rests on identifying biallelic AICDA variants
    (or the dominant C-terminal allele). In the Latin American registry only
    37 of 58 clinically diagnosed patients had a molecular defect identified,
    so a negative panel does not exclude the syndrome.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  evidence:
  - reference: PMID:24402618
    reference_title: "First report of the Hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 58 patients from 51 families reported to the registry with the clinical phenotype of HIGM syndrome, molecular defects were identified in 37 patients thus far."
    explanation: >-
      Quantifies the molecular yield against the clinical phenotype in a
      registry cohort.
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fifteen distinct AID mutations were found but there was no significant genotype-phenotype correlation."
    explanation: >-
      Establishes the allelic heterogeneity found on sequencing, and that the
      variant identified does not predict severity.
differential_diagnoses:
- name: Hyper-IgM syndrome type 1 (CD40 ligand deficiency)
  description: >-
    The X-linked CD40LG defect produces the same serum immunoglobulin pattern,
    and separating the two is the defining diagnostic act in a boy with
    hyper-IgM. The discriminator is opportunistic infection: CD40L deficiency
    additionally loses T-cell licensing of macrophages and dendritic cells, so
    Pneumocystis, Cryptosporidium, and the fungal and opportunistic infections
    of the registry cohort belong to it, not to AID deficiency, whose defect is
    B-cell intrinsic. Massive lymphoid hyperplasia points the other way.
  disease_term:
    preferred_term: hyper-IgM syndrome type 1
    term:
      id: MONDO:0010626
      label: hyper-IgM syndrome type 1
  distinguishing_features:
  - Opportunistic and fungal infections, neutropenia, and sclerosing cholangitis occur in CD40L deficiency but not in AID deficiency.
  - Germinal-center hyperplasia with marked lymphadenopathy and preserved cell-mediated immunity characterize AID deficiency.
  - Inheritance differs — X-linked for CD40L deficiency, autosomal recessive for AID deficiency.
  evidence:
  - reference: PMID:24402618
    reference_title: "First report of the Hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Previously undescribed fungal and opportunistic infections were observed in CD40L-deficient patients but not in the two patients with AID deficiency."
    explanation: >-
      The registry states the discriminating observation directly: the
      opportunistic-infection burden separates CD40L deficiency from AID
      deficiency.
- name: Hyper-IgM syndrome type 3 (CD40 deficiency)
  description: >-
    Biallelic CD40 loss is the autosomal recessive phenocopy of CD40L
    deficiency — the same receptor-ligand axis failing from the B-cell and
    myeloid side. It shares the opportunistic-infection susceptibility that
    distinguishes the CD40 axis from AID deficiency, and so sits on the same
    side of the discriminator.
  disease_term:
    preferred_term: hyper-IgM syndrome type 3
    term:
      id: MONDO:0011735
      label: hyper-IgM syndrome type 3
  distinguishing_features:
  - Autosomal recessive like AID deficiency, but with the opportunistic infections of a CD40-axis defect.
  - IUIS places CD40 deficiency in Table 1 (combined immunodeficiency) rather than among the predominantly antibody deficiencies.
progression:
- phase: Diagnosis and long-term follow-up
  age_range: Median 4.9 years at diagnosis (range 0-53); median 14.2 years at last evaluation (range 2.7-63)
  notes: >-
    AID deficiency is not a neonatal presentation: in the 29-patient European
    cohort the median age at diagnosis was nearly five years, and patients were
    followed into adulthood, with the oldest evaluated at 63. Lymphoid
    hyperplasia developed in 22 of 29 patients but persisted in only 7 at last
    follow-up, so the germinal-center hyperplasia is not uniformly progressive.
  evidence:
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients' median age at diagnosis and at last evaluation was 4.9 years (range: 0 to 53) and 14.2 years (range: 2.7 to 63), respectively."
    explanation: >-
      Gives the diagnostic delay and the follow-up span in the defining cohort.
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lymphoid hyperplasia developed in 22 patients and persisted in 7 at last follow-up."
    explanation: >-
      Documents that the lymphoid hyperplasia regresses in most patients rather
      than progressing.
clinical_burden:
  burden_level: MODERATE
  rationale: >-
    The infectious burden is largely correctable: immunoglobulin replacement
    produced a dramatic fall in infections in the defining cohort, and unlike
    CD40L deficiency there is no mortality driver from opportunistic infection
    or from sclerosing cholangitis — no deaths were attributed to AID
    deficiency in the Latin American registry. The residual burden is autoimmune and
    inflammatory disease, which affected roughly a fifth of the European cohort
    and is not addressed by replacement therapy.
  evidence:
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most patients had suffered from recurrent and severe infections, however, intravenous immunoglobulin (IVIG) replacement therapy resulted in a dramatic decrease in the number of infections."
    explanation: >-
      Establishes that the infectious component of the burden is largely
      correctable with replacement therapy.
  - reference: PMID:14962793
    reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is striking to note that six patients developed autoimmune or inflammatory disorders including diabetes mellitus, polyarthritis, autoimmune hepatitis, hemolytic anemia, immune thrombocytopenia, Crohn's disease and chronic uveitis."
    explanation: >-
      Quantifies the autoimmune/inflammatory burden that replacement therapy
      does not address (6 of 29 patients).
treatments:
- name: Immunoglobulin Replacement Therapy
  description: >-
    Regular intravenous or subcutaneous immunoglobulin replacement is the
    cornerstone of management. It supplies the IgG that patients cannot make
    and produces a marked reduction in infection frequency; early initiation
    may also prevent the lymphoid hyperplasia. It does not correct the
    underlying enzymatic defect.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: immunoglobulin replacement therapy
    term:
      id: NCIT:C62710
      label: Immunoglobulin Therapy
  target_mechanisms:
  - target: Loss of Opsonizing and Mucosal Antibody Function
    treatment_effect: BYPASSES
    description: >-
      Passive IgG supplies the opsonizing antibody the patient cannot generate,
      bypassing rather than repairing the class-switch block.
    evidence:
    - reference: PMID:14962793
      reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        intravenous immunoglobulin (IVIG) replacement therapy resulted in a
        dramatic decrease in the number of infections
      explanation: >-
        IVIG replacement dramatically reduced infections in the cohort,
        confirming it substitutes for the missing antibody function.
  - target: Massive Lymphoid Hyperplasia
    treatment_effect: INHIBITS
    description: >-
      Early-onset immunoglobulin replacement may prevent the lymphoid
      hyperplasia as well as the infections.
    evidence:
    - reference: PMID:14962793
      reference_title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        AID-deficient patients are prone to infections and lymphoid
        hyperplasia, which may be prevented by early-onset IVIG replacement
      explanation: >-
        The authors conclude that early IVIG may prevent lymphoid hyperplasia
        as well as infection; "may" is preserved here as a hedged claim.
  evidence:
  - reference: PMID:36931691
    reference_title: "Type 2 hyper-IgM syndrome with a rare variant of AICDA gene mutation in a young woman."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The patient was started on monthly intravenous immunoglobulin replacement
      therapy and is currently symptomatically better
    explanation: >-
      Monthly IVIG is the treatment given to a genetically confirmed HIGM2
      patient, with symptomatic improvement.
- name: Antibiotic Therapy and Prophylaxis
  description: >-
    Antibiotics treat the recurrent bacterial sinopulmonary and mucosal
    infections, and prophylactic regimens are used alongside immunoglobulin
    replacement in patients with continuing infection or established
    bronchiectasis.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
  target_mechanisms:
  - target: Recurrent Bacterial Sinopulmonary and Mucosal Infection
    treatment_effect: INHIBITS
    description: >-
      Antibiotics eradicate or suppress the bacterial infections that the
      missing switched antibody cannot prevent or clear.
  notes: >-
    No AID-deficiency-specific antibiotic trial exists; use follows general
    primary-antibody-deficiency practice, so no evidence item is attached to
    this treatment rather than citing a source that does not address HIGM2.
- name: Hematopoietic Cell Transplantation (rarely indicated)
  description: >-
    Unlike the CD40L and CD40 hyper-IgM syndromes — where the combined
    immunodeficiency and its opportunistic infections make transplantation a
    standard consideration — HIGM2 is a B-cell-intrinsic antibody deficiency
    that is generally well controlled by immunoglobulin replacement, and
    transplantation is not a routine indication. This entry records the
    contrast rather than asserting a HIGM2 transplantation indication: in the
    Latin American registry the transplanted patients were CD40L-deficient, and
    all AID-deficient patients were alive on conventional management.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: hematopoietic cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  evidence:
  - reference: PMID:24402618
    reference_title: "First report of the Hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Four CD40L-deficient patients underwent successful bone marrow
      transplantation.
    explanation: >-
      In the registry transplantation was performed in CD40L-deficient
      patients; none of the AID-deficient patients was transplanted, supporting
      the statement that HSCT is not a routine HIGM2 indication.
discussions:
- discussion_id: higm2_population_prevalence_unknown
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - prevalence#Worldwide
  prompt: >-
    What is the population prevalence of AID deficiency, and does it differ
    between populations with high and low rates of consanguinity?
  rationale: >-
    Every published estimate of HIGM2 frequency is a referral-based case count
    rather than a denominator-based rate, so the disease's true prevalence is
    unknown. Because it is autosomal recessive, prevalence should be markedly
    higher in populations with high consanguinity — the original cohorts drew
    heavily on Turkish and Middle Eastern families — but no population-based
    screening study has tested this. Without a denominator it is impossible to
    say what fraction of AID-deficient people are diagnosed, and the
    consistently mild infectious phenotype relative to CD40L deficiency makes
    under-ascertainment plausible.
- discussion_id: higm2_aid_tolerance_direct_or_indirect
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Breakdown of B-Cell Self-Tolerance
  prompt: >-
    Is the tolerance defect in AID deficiency a direct consequence of losing
    deaminase activity in developing B cells, or an indirect consequence of the
    abnormal germinal-center environment?
  rationale: >-
    AID is required for removal of autoreactive B cells at both the central and
    peripheral checkpoints, but the central checkpoint operates in the bone
    marrow, before B cells enter a germinal center and before AID is
    conventionally described as being expressed. Whether the tolerance defect
    reflects a distinct, low-level developmental role for AID or is secondary
    to systemic effects of the failed germinal-center reaction is unresolved,
    and it determines whether autoimmunity in HIGM2 could be predicted from
    genotype or only observed.
references:
- reference: PMID:11007475
  title: "Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)."
- reference: PMID:11007474
  title: "Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme."
- reference: PMID:14962793
  title: "Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency."
- reference: PMID:15893695
  title: "Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2."
- reference: PMID:21700883
  title: "Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans."
- reference: PMID:17560278
  title: "Pathophysiology of B-cell intrinsic immunoglobulin class switch recombination deficiencies."
- reference: PMID:24402618
  title: "First report of the Hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes."
- reference: PMID:32423680
  title: "From Dysgammaglobulinemia to Autosomal-Dominant Activation-Induced Cytidine Deaminase Deficiency: Unraveling an Inherited Immunodeficiency after 50 Years."
- reference: PMID:36931691
  title: "Type 2 hyper-IgM syndrome with a rare variant of AICDA gene mutation in a young woman."
- reference: PMID:35748970
  title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
📚

References & Deep Research

References

10
Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).
No top-level findings curated for this source.
Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.
No top-level findings curated for this source.
Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency.
No top-level findings curated for this source.
Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2.
No top-level findings curated for this source.
Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans.
No top-level findings curated for this source.
Pathophysiology of B-cell intrinsic immunoglobulin class switch recombination deficiencies.
No top-level findings curated for this source.
First report of the Hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes.
No top-level findings curated for this source.
From Dysgammaglobulinemia to Autosomal-Dominant Activation-Induced Cytidine Deaminase Deficiency: Unraveling an Inherited Immunodeficiency after 50 Years.
No top-level findings curated for this source.
Type 2 hyper-IgM syndrome with a rare variant of AICDA gene mutation in a young woman.
No top-level findings curated for this source.
Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.
No top-level findings curated for this source.